martes, 10 de septiembre de 2024

The Lancet Oncology in conversation with Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

https://thelancetoncology.buzzsprout.com/1391338/15623788-kanwal-raghav-on-trastuzumab-deruxtecan-in-her2-positive-advanced-colorectal-cancer-destiny-crc02?utm_campaign=update-lanonc&utm_medium=email&_hsenc=p2ANqtz--dVhZXPSvlrWoMnKvLVeWYrHf8E_5sVn27O1POuNCCwY0EFwOWlu70hQt3QdX3rdPaMp3Rjp4w5nVjJNQ_khML6HGBCA&_hsmi=323800094&utm_content=323781618&utm_source=hs_email

No hay comentarios:

Publicar un comentario